{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:56:48Z","timestamp":1790801808511,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Post-Doctoral Fellowship 2022 (Reinventing University), Chiang Mai University (CMU), Thailand","award":["PD2565"],"award-info":[{"award-number":["PD2565"]}]},{"name":"a Distinguished Professor Dr. Somdet Srichairatanakool, PhD., National Research Council of Thailand","award":["N42A670732"],"award-info":[{"award-number":["N42A670732"]}]},{"name":"a Distinguished Professor Dr. Somdet Srichairatanakool, PhD., National Research Council of Thailand","award":["N42A670732"],"award-info":[{"award-number":["N42A670732"]}]},{"name":"a Distinguished Professor Dr. Somdet Srichairatanakool, PhD., National Research Council of Thailand","award":["N42A670732"],"award-info":[{"award-number":["N42A670732"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatocellular carcinoma (HCC) is one of the life\u2013threatening cancers in the current decade. Earlier reports suggest that protein arginine methyl transferase 5 (PRMT5) is also linked with HCC, and the symmetrically dimethylated arginine marks created by PRMT5 are read by the Staphylococcal nuclease domain-containing protein 1 (SND1), which eventually can drive HCC development. Indeed, as no inhibitors have been ascertained for SND1, we aimed to screen for new inhibitors with specificity and high affinity towards the active site of SND1. In this study, we first used the Gene Set Cancer Analysis (GSCA) dataset to evaluate the expression of SND1 in HCC. Accordingly, SND1 is the highly overexpressed gene in HCC and its overexpression affects the overall survival of HCC patients. Then, we employed a virtual screening approach to identify potential inhibitors from the ASINEX database. We utilized molecular docking to single out the potential top hits based on the docking score and mode of interaction with the SND1 active site. In the prediction, we found [4\u2013(5,6,7,8\u2013tetrahydro\u20134\u00a0H\u2013cyclohepta[c][1,2]oxazol\u20133\u2013yl)piperidin\u20131\u2013yl]\u2013[4\u2013(trifluoromethyl)phenyl]methanone (TOP1: -10.4\u00a0kcal\/mol) and 1\u2013[2\u2013hydroxy\u20132\u2013(1\u2013methylsulfonyl\u20133,4\u2013dihydro\u20132\u00a0H\u2013quinolin\u20136\u2013yl)ethyl]\u20134\u2013(4\u2013methylphenyl)piperidin\u20134\u2013ol (TOP2: -10.3\u00a0kcal\/mol) as promising candidates than reference compound (STD: -4.6\u00a0kcal\/mol). Further molecular dynamics simulations and a pharmacokinetic properties study indicate that TOP2 exhibits a more stable binding with the SND1 active site and complies with Lipinski\u2019s rule of five for drug-likeness, with no observed toxicity and good pharmacokinetic properties.<\/jats:p>","DOI":"10.1038\/s41598-025-14878-0","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T06:38:58Z","timestamp":1755758338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of novel SND1 inhibitors by in silico\u2013based molecular docking and dynamics simulation methods for managing hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuvaraj","family":"Ravikumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirajunnisa Abdul","family":"Razack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Sivashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirichai","family":"Srichairatanakool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimpisid","family":"Koonyosying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somdet","family":"Srichairatanakool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"10","key":"14878_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. R. A global view of hepatocellular carcinoma: trends, risk, prevention, and management. Nat. Rev. Gastroenterol. Hepatol. 16 (10), 589\u2013604 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"14878_CR2","first-page":"33","volume":"3","author":"E Kaya","year":"2022","unstructured":"Kaya, E., Mazzolini, G. D., Yilmaz, Y. & Canbay, A. Prevention of hepatocellular carcinoma and monitoring of high-risk patients. Hepatol. Forum. 3 (1), 33\u201338 (2022).","journal-title":"Hepatol. Forum"},{"issue":"1","key":"14878_CR3","doi-asserted-by":"publisher","first-page":"e000260","DOI":"10.1136\/bmjgast-2018-000260","volume":"6","author":"H Matsushita","year":"2019","unstructured":"Matsushita, H. & Takaki, A. Alcohol and hepatocellular carcinoma. BMJ Open. Gastroenterol. 6 (1), e000260 (2019).","journal-title":"BMJ Open. Gastroenterol."},{"issue":"1","key":"14878_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal. Transduct. Target. Ther. 8 (1), 92 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"14878_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/BST20221147","volume":"51","author":"Y Wang","year":"2023","unstructured":"Wang, Y. & Bedford, M. T. Effectors and effects of arginine methylation. Biochem. Soc. Trans. 51 (2), 725\u2013734 (2023).","journal-title":"Biochem. Soc. Trans."},{"key":"14878_CR6","doi-asserted-by":"crossref","unstructured":"Wolinska, E. & Skrzypczak, M. Epigenetic changes affecting the development of hepatocellular carcinoma. Cancers 13(16), 4237\u20134251 (2021).","DOI":"10.3390\/cancers13164237"},{"issue":"8","key":"14878_CR7","first-page":"2150","volume":"21","author":"AT Norah","year":"2023","unstructured":"Norah, A. T., Claire, F., Marina, B., Michael, C. & Julie, A. Liver transplantation: status report, current and future challenges. CGH 21 (8), 2150\u20132166 (2023).","journal-title":"CGH"},{"issue":"1","key":"14878_CR8","first-page":"1","volume":"5","author":"Z Wu","year":"2023","unstructured":"Wu, Z., Liu, Y., Zhang, M. & Wang, D. Emerging posttranslational modifications and their roles in DNA damage response. GIAD 5 (1), 1\u201316 (2023).","journal-title":"GIAD"},{"issue":"4","key":"14878_CR9","first-page":"277","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Zhang, M. & Wang, Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. JNCI 2 (4), 277\u2013290 (2022).","journal-title":"JNCI"},{"issue":"2","key":"14878_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes12020208","volume":"12","author":"A Majchrzak-Celinska","year":"2021","unstructured":"Majchrzak-Celinska, A., Warych, A. & Szoszkiewicz, M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes 12 (2), 1\u201321 (2021).","journal-title":"Genes"},{"key":"14878_CR11","doi-asserted-by":"publisher","first-page":"690057","DOI":"10.3389\/fphar.2021.690057","volume":"12","author":"WM Zhou","year":"2021","unstructured":"Zhou, W. M. et al. Methylation landscape: targeting writer or eraser to discover anti\u2013cancer drug. Front. Pharmacol. 12, 690057 (2021).","journal-title":"Front. Pharmacol."},{"key":"14878_CR12","doi-asserted-by":"publisher","first-page":"1086421","DOI":"10.1016\/j.jmgm.2023.108642","volume":"126","author":"S Barman","year":"2024","unstructured":"Barman, S., Bardhan, I., Padhan, J. & Sudhamalla, B. Integrated virtual screening and MD simulation approaches toward discovering potential inhibitors for targeting BRPF1 bromodomain in hepatocellular carcinoma. J. Mol. Graph Model. 126, 1086421\u20131086418 (2024).","journal-title":"J. Mol. Graph Model."},{"issue":"13","key":"14878_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20133322","volume":"20","author":"MD Fulton","year":"2019","unstructured":"Fulton, M. D., Brown, T. & George Zheng, Y. The biological axis of protein arginine methylation and asymmetric dimethylarginine. Int. J. Mol. Sci. 20 (13), 1\u201318 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"14878_CR14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/srep01311","volume":"3","author":"S Dhar","year":"2013","unstructured":"Dhar, S. et al. Loss of the major type in arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. Sci. Rep. 3, 1311 (2013).","journal-title":"Sci. Rep."},{"issue":"8","key":"14878_CR15","first-page":"702","volume":"1839","author":"S Gayatri","year":"2014","unstructured":"Gayatri, S. & Bedford, M. T. Readers of histone Methylarginine marks. BBA-Gene Regul. Mech. 1839 (8), 702\u2013710 (2014).","journal-title":"BBA-Gene Regul. Mech."},{"issue":"3","key":"14878_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/cam4.1360","volume":"7","author":"H Jiang","year":"2018","unstructured":"Jiang, H. et al. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma. Cancer Med. 7 (3), 869\u2013882 (2018).","journal-title":"Cancer Med."},{"key":"14878_CR17","doi-asserted-by":"crossref","unstructured":"Jiang, Y. et al. Integrative evaluation of the clinical significance underlying protein arginine methyltransferases in hepatocellular carcinoma. Cancers 15(16), 4183\u20134203 (2023).","DOI":"10.3390\/cancers15164183"},{"issue":"2","key":"14878_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/carcin\/bgz065","volume":"41","author":"K Zhu","year":"2020","unstructured":"Zhu, K. et al. Metadher-in-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-\u00df-catenin signaling pathway. Carcinog 41 (2), 130\u2013138 (2020).","journal-title":"Carcinog"},{"key":"14878_CR19","doi-asserted-by":"crossref","unstructured":"Wright, T., Wang, Y. & Bedford, M. T. The role of the PRMT5\u2013SND1 axis in hepatocellular carcinoma. Epigenomes 5(1), 2\u201323 (2021).","DOI":"10.3390\/epigenomes5010002"},{"issue":"22","key":"14878_CR20","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1042\/BCJ20230384","volume":"480","author":"T Wright","year":"2023","unstructured":"Wright, T. et al. Loss of the Methylarginine reader function of SND1 confers resistance to hepatocellular carcinoma. Biochem. J. 480 (22), 1805\u20131816 (2023).","journal-title":"Biochem. J."},{"issue":"12","key":"14878_CR21","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-17-0298","volume":"77","author":"N Jariwala","year":"2017","unstructured":"Jariwala, N. et al. Oncogenic role of SND1 in development and progression of hepatocellular carcinoma. Cancer Res. 77 (12), 3306\u20133316 (2017).","journal-title":"Cancer Res."},{"issue":"5","key":"14878_CR22","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/hep.24216","volume":"53","author":"BK Yoo","year":"2011","unstructured":"Yoo, B. K. et al. Increased RNA\u2013induced Silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology 53 (5), 1538\u20131548 (2011).","journal-title":"Hepatology"},{"key":"14878_CR23","doi-asserted-by":"crossref","unstructured":"Ravikumar, Y. et al. In Silico molecular Docking and dynamics simulation analysis of potential histone lysine Methyl transferase inhibitors for managing \u03b2\u2013thalassemia. Molecules 28(21), 7266\u20137285 (2023).","DOI":"10.3390\/molecules28217266"},{"issue":"11","key":"14878_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 29 (11), 1859\u20131865 (2008).","journal-title":"J. Comput. Chem."},{"issue":"7","key":"14878_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/2394-5079.2018.34","volume":"4","author":"S Chidambaranathan-Reghupaty","year":"2018","unstructured":"Chidambaranathan-Reghupaty, S., Mendoza, R., Fisher, P. B. & Sarkar, D. The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. Hepatoma Res. 4 (7), 1\u201310 (2018).","journal-title":"Hepatoma Res."},{"issue":"43","key":"14878_CR26","doi-asserted-by":"publisher","first-page":"18398","DOI":"10.1073\/pnas.1013106107","volume":"107","author":"K Liu","year":"2010","unstructured":"Liu, K. et al. Structural basis for recognition of arginine methylated Piwi proteins by the extended Tudor domain. PNAS 107 (43), 18398\u201318403 (2010).","journal-title":"PNAS"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14878-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:07:47Z","timestamp":1757441267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14878-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14878"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14878-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30701"}}